Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

768
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
768
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

720
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
720
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

273
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
273
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

821
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
821
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

225
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
225

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry.

JAMA·2026
Same author

Patient Perspectives on Cardiac Gene Therapy: A Survey of Knowledge, Attitudes, and Educational Needs.

Journal of cardiac failure·2026
Same author

Cardiology Provider Knowledge and Attitudes Toward Cardiac Gene Therapy: A Multi-Institutional National Survey.

JACC. Heart failure·2026
Same author

Angiotensin-Neprilysin Inhibition and Renal Outcome in Men and Women With Heart Failure.

Journal of the American Heart Association·2026
Same author

Finerenone and polypharmacy in heart failure with mildly reduced or preserved ejection fraction: a marker of risk, not a barrier to therapy.

European journal of heart failure·2026
Same author

Health status trajectories using Markov modeling in patients with heart failure with preserved ejection fraction.

Revista espanola de cardiologia (English ed.)·2026
Same journal

A high proportion of children with severe cardiomyopathies show both myocarditis and genetic predispositions.

European journal of heart failure·2026
Same journal

Correction to: Association of patient-centred remote monitoring with clinical outcomes in patients with prior hospitalization: the TELESAT PRIOR-HF study.

European journal of heart failure·2026
Same journal

Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors.

European journal of heart failure·2026
Same journal

"Reply to Murthy et al. regarding AI-derived LVOT-VTI for monitoring disease progression in transthyretin cardiac amyloidosis".

European journal of heart failure·2026
Same journal

High serum transthyretin concentrations identify a low likelihood of advanced myocardial amyloid burden in suspected ATTR cardiomyopathy.

European journal of heart failure·2026
Same journal

Consistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial.

European journal of heart failure·2026
See all related articles

Related Experiment Video

Updated: Jan 20, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K

Heart failure around the world.

Jasper Tromp1,2,3, João Pedro Ferreira4, Satit Janwanishstaporn5

  • 1National Heart Centre Singapore, Singapore.

European Journal of Heart Failure
|August 17, 2019
PubMed
Summary
This summary is machine-generated.

Global heart failure trials face challenges due to diverse patient populations and healthcare practices worldwide. Socioeconomic factors significantly influence patient enrollment and outcomes in these large-scale studies.

Keywords:
Geographic differencesHeart failureOutcomeSocioeconomic status

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Related Experiment Videos

Last Updated: Jan 20, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.3K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Area of Science:

  • Cardiology
  • Clinical Trials
  • Global Health

Background:

  • Heart failure outcome trials increasingly require large, global patient cohorts.
  • Significant heterogeneity exists in patient populations across countries due to varying background therapies, socioeconomic status, and healthcare practices.
  • Socioeconomic determinants, rather than geography, are increasingly recognized as drivers of this heterogeneity.

Purpose of the Study:

  • To evaluate regional differences in patient characteristics and outcomes in heart failure epidemiologic studies.
  • To assess the worldwide representativeness of clinical trial populations in heart failure research.
  • To investigate the role of socioeconomic determinants in country-level differences in heart failure trial enrollment and clinical outcomes.

Main Methods:

  • Review of recent epidemiologic studies on heart failure.
  • Analysis of clinical trial data for global representativeness.
  • Assessment of socioeconomic factors influencing trial enrollment and outcomes.

Main Results:

  • Identified significant regional variations in patient characteristics and outcomes in heart failure.
  • Highlighted disparities in the representativeness of global clinical trial populations.
  • Confirmed the substantial impact of socioeconomic determinants on heart failure trial enrollment and patient outcomes across countries.

Conclusions:

  • Socioeconomic factors are critical determinants of heterogeneity in global heart failure trials.
  • Addressing socioeconomic disparities is essential for equitable and representative heart failure research.
  • Future trial designs must account for socioeconomic variations to ensure generalizability and improve patient care worldwide.